- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.03.2025 | 746 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.03.2025ISIN NameCA3719571018 GENESIS... ► Artikel lesen | |
| 12.03. | BenevolentAI: Result of Extraordinary General Meeting and Delisting from Euronext Amsterdam | 461 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that:
All resolutions proposed at its Extraordinary... ► Artikel lesen | |
| 12.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.03.2025 | 615 | Xetra Newsboard | Das Instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 12.03.2025 und ex Kapitalmassnahme am 13.03.2025 The instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY... ► Artikel lesen | |
| BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
| 06.02. | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 740 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen | |
| 11.12.24 | BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission | 395 | Business Wire | Changes mark a return to BenevolentAI's foundational strengths Initiates significant organisational restructuring Announces intention to evaluate delisting from Euronext Amsterdam
Regulatory... ► Artikel lesen | |
| 17.10.24 | BenevolentAI Appoints Kenneth Mulvany as Executive Chairman | 304 | Business Wire | Founder of leading AI drug discovery company returns to the executive management team to capitalise on the growing adoption of AI in drug discovery and development
BenevolentAI ("BenevolentAI"... ► Artikel lesen | |
| 10.10.24 | BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024 | 359 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology... ► Artikel lesen | |
| 19.09.24 | BenevolentAI Interim Results for the Six Months Ended 30 June 2024 | 450 | Business Wire | Strengthened Executive Leadership and Board Positive Top Line Phase I Data Reported for BEN-8744, Full Data to be Presented at Upcoming Leading Medical Conference Advancements in Target Identification... ► Artikel lesen | |
| 06.09.24 | BenevolentAI Notice of Interim Results | 440 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its interim results for the six months... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 4,805 | +0,84 % | Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares | ||
| ABCELLERA BIOLOGICS | 3,755 | +5,06 % | AbCellera Biologics stock rating maintained at Hold by Benchmark | ||
| ANAVEX LIFE SCIENCES | 8,394 | +0,99 % | Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows | ||
| VERACYTE | 25,000 | -1,57 % | S&P Dow Jones Indices: Veracyte Set to Join S&P SmallCap 600 | NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the... ► Artikel lesen | |
| ASCLETIS PHARMA | 1,550 | +5,44 % | Ascletis Pharma Inc.: Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an ... | - Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction... ► Artikel lesen | |
| BIOMEA FUSION | 1,795 | +0,56 % | Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights | Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients... ► Artikel lesen | |
| JASPER THERAPEUTICS | 2,930 | +2,45 % | JMP reiterates Market Outperform rating on Jasper Therapeutics stock | ||
| ABSCI | 2,565 | 0,00 % | Absci Corporation: Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results | Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half... ► Artikel lesen | |
| LANTERN PHARMA | 4,490 | +0,45 % | RedChip Companies, Inc.: RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 | ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, will host an exclusive... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 8,535 | +0,12 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
| QIAGEN | 42,580 | +0,69 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen nach einer Investorenveranstaltung auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Das Interesse der Teilnehmer... ► Artikel lesen | |
| EVOTEC | 6,116 | -2,36 % | Evotec-Aktie: Neue Tiefs in Sicht? Nur ein Wunder kann jetzt wohl noch helfen! | © Foto: Foto von Anna Shvets auf PexelsDie Hamburger Biotechfirma Evotec kämpft ums Überleben. Das traditionelle Geschäft mit der Wirkstoffforschung bricht weg, während die hochgelobte Biologics-Sparte... ► Artikel lesen | |
| THARIMMUNE | 5,850 | +61,16 % | Tharimmune Inc.: Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments | RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen | |
| VIKING THERAPEUTICS | 21,975 | -0,29 % | Opening Bell: Lowe's, Micron Technology, Hertz, Viking Therapeutics, Target, Pop Mart | Die Wall Street hat einen höchst durchwachsenen Handelstag hinter sich. Der Dow Jones gab nach einem Rekordhoch fast alle Gewinne ab. Der Nasdaq 100 rutschte sogar deutlich in die Verlustzone. Auch... ► Artikel lesen | |
| BIONTECH | 95,65 | +0,21 % | Warten auf den Durchbruch: Steht die Mega-Rallye bei der BioNTech-Aktie kurz bevor? | Investoren warten bei BioNTech auf neue Produkte. Einen aussichtsreichen Kandidaten hat der Biotechkonzern. Eine Milliardenkooperation ist bereits geschlossen. Zudem ist die Kasse gut gefüllt Seit Frühjahr... ► Artikel lesen |
BENEVOLENTAI gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,087 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.